搜尋結果
A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ), the virus that causes coronavirus disease 2019 ( COVID‑19 ). Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing ...
- none
- Intramuscular
- mRNA, viral, inactivated, protein
- SARS-CoV-2
The COVID-19 pandemic, also known as the coronavirus pandemic, is a global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The novel virus was first identified in an outbreak in Wuhan, the capital of Hubei, China, in December 2019, before it spread to other areas of Asia, and then worldwide in early 2020.
- 6,956,160 (reported), 17.5–31.4 million (estimated)
- Worldwide
- Coronavirus disease 2019 (COVID-19)
- Severe acute respiratory syndromecoronavirus 2 (SARS‑CoV‑2)
Skycovione is a COVID-19 vaccine candidate developed by SK Bioscience and the Institute for Protein Design of the University of Washington, [2] [3] [4] [5] [6] [7] [8] It is South Korea's first homegrown COVID-19 vaccine [9] and utilizes GSK 's AS03 adjuvant technology. The phase III clinical trial involves 4,037 participants.
- GBP510, Skycovion
- SARS-CoV-2
- 新冠肺炎-疫苗資訊最前線
18.2–33.5 million [6] (estimated) Coronavirus disease 2019 ( COVID-19) is a contagious disease caused by the coronavirus SARS-CoV-2. The first known case was identified in Wuhan, China, in December 2019. [7] Most scientists believe the SARS-CoV-2 virus entered into human populations through natural zoonosis, similar to the SARS-CoV-1 and MERS ...
- 6,960,770 (reported), 17.6–31.4 million (estimated)
- SARS-CoV-2
- 2–14 days (typically 5), after infection
- Symptomatic and supportive
v. t. e. The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, [2] the Sinopharm COVID-19 vaccine, [3] or BIBP vaccine, [3] [4] [5] is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm 's Beijing Institute of Biological Products (sometimes written as Beijing Bio-Institute of Biological Products, [6] resulting ...
Covaxin (development name, BBV152) is a whole inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology. On 3 November 2021, the World Health Organization (WHO) validated the vaccine for emergency use, as the first Indian-developed covid vaccine to be approved.
Timeline. Locations. International response. Medical response. Variants. Economic impact and recession. Impacts. COVID-19 portal. v. t. e. Sinopharm NVSI COVID-19 vaccine, also known as mutI-tri-RBD or NVSI-06-08, is a COVID-19 vaccine developed by National Vaccine & Serum Institute (NVSI, 中生研究院), a subsidiary of CNBG of Sinopharm. [1] [2]
